Anders Neijber - Photocure ASA Clinical Affairs

PHCUF Stock  USD 5.60  1.12  25.00%   

Insider

Anders Neijber is Clinical Affairs of Photocure ASA
Phone47 22 06 22 10
Webhttps://www.photocure.com

Photocure ASA Management Efficiency

The company has return on total asset (ROA) of (0.0309) % which means that it has lost $0.0309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1567) %, meaning that it generated substantial loss on money invested by shareholders. Photocure ASA's management efficiency ratios could be used to measure how well Photocure ASA manages its routine affairs as well as how well it operates its assets and liabilities.
Photocure ASA has accumulated 12.5 M in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Photocure ASA has a current ratio of 4.4, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Photocure ASA until it has trouble settling it off, either with new capital or with free cash flow. So, Photocure ASA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Photocure ASA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Photocure to invest in growth at high rates of return. When we think about Photocure ASA's use of debt, we should always consider it together with cash and equity.
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway. Photocure ASA operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 97 people. Photocure ASA [PHCUF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Photocure ASA Leadership Team

Elected by the shareholders, the Photocure ASA's board of directors comprises two types of representatives: Photocure ASA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Photocure. The board's role is to monitor Photocure ASA's management team and ensure that shareholders' interests are well served. Photocure ASA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Photocure ASA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tolv Hillestad, Group Controller
Erik Dahl, Chief Officer
Patricia Kelly, VP HR
David Moskowitz, Head Relations
Daniel Schneider, President CEO
Anders Neijber, Clinical Affairs
Kari MD, Head Devel
Geoffrey Coy, VP Operations

Photocure Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Photocure ASA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Photocure Pink Sheet

Photocure ASA financial ratios help investors to determine whether Photocure Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Photocure with respect to the benefits of owning Photocure ASA security.